These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 19050697)

  • 1. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin.
    Pestina TI; Hargrove PW; Jay D; Gray JT; Boyd KM; Persons DA
    Mol Ther; 2009 Feb; 17(2):245-52. PubMed ID: 19050697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells.
    Urbinati F; Hargrove PW; Geiger S; Romero Z; Wherley J; Kaufman ML; Hollis RP; Chambers CB; Persons DA; Kohn DB; Wilber A
    Exp Hematol; 2015 May; 43(5):346-351. PubMed ID: 25681747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Optimized γ-Globin Lentiviral Vector GGHI-mB-3D Leads to Nearly Therapeutic HbF Levels In Vitro in CD34
    Drakopoulou E; Georgomanoli M; Lederer CW; Panetsos F; Kleanthous M; Voskaridou E; Valakos D; Papanikolaou E; Anagnou NP
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.
    Wilber A; Hargrove PW; Kim YS; Riberdy JM; Sankaran VG; Papanikolaou E; Georgomanoli M; Anagnou NP; Orkin SH; Nienhuis AW; Persons DA
    Blood; 2011 Mar; 117(10):2817-26. PubMed ID: 21156846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number.
    Persons DA; Hargrove PW; Allay ER; Hanawa H; Nienhuis AW
    Blood; 2003 Mar; 101(6):2175-83. PubMed ID: 12411297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia.
    Zhao HF; Abraham A; Kim YS; Wang YD; Pestina T; Zhan J; Humphries K; Nienhuis AW; Persons DA
    Mol Ther; 2017 Mar; 25(3):593-605. PubMed ID: 28190779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
    Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
    Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia.
    Hanawa H; Hargrove PW; Kepes S; Srivastava DK; Nienhuis AW; Persons DA
    Blood; 2004 Oct; 104(8):2281-90. PubMed ID: 15198957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.
    Perumbeti A; Higashimoto T; Urbinati F; Franco R; Meiselman HJ; Witte D; Malik P
    Blood; 2009 Aug; 114(6):1174-85. PubMed ID: 19474450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel BaEVRless-Pseudotyped γ-Globin Lentiviral Vector Drives High and Stable Fetal Hemoglobin Expression and Improves Thalassemic Erythropoiesis
    Drakopoulou E; Georgomanoli M; Lederer CW; Kleanthous M; Costa C; Bernadin O; Cosset FL; Voskaridou E; Verhoeyen E; Papanikolaou E; Anagnou NP
    Hum Gene Ther; 2019 May; 30(5):601-617. PubMed ID: 30324804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of lentiviral gene transfer approaches designed to promote fetal hemoglobin production for the treatment of β-hemoglobinopathies.
    Daniel-Moreno A; Lamsfus-Calle A; Wilber A; Chambers CB; Johnston I; Antony JS; Epting T; Handgretinger R; Mezger M
    Blood Cells Mol Dis; 2020 Sep; 84():102456. PubMed ID: 32498026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.
    Uchida N; Hsieh MM; Raines L; Haro-Mora JJ; Demirci S; Bonifacino AC; Krouse AE; Metzger ME; Donahue RE; Tisdale JF
    Nat Commun; 2019 Oct; 10(1):4479. PubMed ID: 31578323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells.
    Papanikolaou E; Georgomanoli M; Stamateris E; Panetsos F; Karagiorga M; Tsaftaridis P; Graphakos S; Anagnou NP
    Hum Gene Ther; 2012 Jan; 23(1):15-31. PubMed ID: 21875313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts.
    Wilber A; Tschulena U; Hargrove PW; Kim YS; Persons DA; Barbas CF; Nienhuis AW
    Blood; 2010 Apr; 115(15):3033-41. PubMed ID: 20190190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-Transcriptional Genetic Silencing of
    Esrick EB; Lehmann LE; Biffi A; Achebe M; Brendel C; Ciuculescu MF; Daley H; MacKinnon B; Morris E; Federico A; Abriss D; Boardman K; Khelladi R; Shaw K; Negre H; Negre O; Nikiforow S; Ritz J; Pai SY; London WB; Dansereau C; Heeney MM; Armant M; Manis JP; Williams DA
    N Engl J Med; 2021 Jan; 384(3):205-215. PubMed ID: 33283990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Induction of Human Fetal Globin Gene in Hydroxyurea-Resistant Primary Adult Erythroid Cells.
    Chou YC; Chen RL; Lai ZS; Song JS; Chao YS; Shen CK
    Mol Cell Biol; 2015 Jul; 35(14):2541-53. PubMed ID: 25986606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and IND-enabling studies of a novel Cas9 genome-edited autologous CD34
    Katta V; O'Keefe K; Li Y; Mayuranathan T; Lazzarotto CR; Wood RK; Levine RM; Powers A; Mayberry K; Manquen G; Yao Y; Zhang J; Jang Y; Nimmagadda N; Dempsey EA; Lee G; Uchida N; Cheng Y; Fazio F; Lockey T; Meagher M; Sharma A; Tisdale JF; Zhou S; Yen JS; Weiss MJ; Tsai SQ
    Mol Ther; 2024 Oct; 32(10):3433-3452. PubMed ID: 39086133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.